Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa
Saroukos, chief financial officer, has decided to leave Takeda to
return to his home-country of Australia to be closer to family. Mr.
Saroukos will step down as CFO, effective April 1, 2024 and will
remain with the company as a board director until June 28, 2024.
Milano Furuta, president of Takeda’s Japan Pharma Business Unit
(JPBU), will succeed Mr. Saroukos, effective April 1, 2024. Mr.
Furuta will report to Christophe Weber, president & CEO, and
will be based in Tokyo, Japan. As CFO, Mr. Furuta will be proposed
to the board of directors as a candidate for election to the
board.
Christophe Weber commented: “On behalf of Takeda’s
executive team and board of directors, I would like to thank Costa
for his outstanding contributions and leadership. He has been a key
driver of Takeda’s transformation and a trusted advisor to me and
the board. He has also built a strong finance function and culture
that will serve Takeda well for years to come. I wish Costa all the
best as he returns to his home country to be closer to his
family.”
Mr. Saroukos has played a pivotal role in Takeda’s
transformation into a global biopharmaceutical company. His
leadership during the acquisition and integration of Shire PLC.,
the largest-ever overseas acquisition by a Japanese company, was a
critical factor in the deal’s success, and his financial
stewardship has helped position the company for a renewed focus on
growth investment and shareholder returns. He joined Takeda in 2015
as the CFO of the EUCAN [Europe and Canada] Business Unit and was
appointed global CFO in April 2018.
Prior to joining Takeda in 2010, Mr. Furuta worked as an equity
research analyst at an investment management firm in the United
States. Mr. Furuta began his career in 2000 in banking and private
equity investment in Japan, where he was involved with several
types of financial transactions, including leveraged buyouts and
debt restructuring. Before becoming JPBU president, Mr. Furuta
served as corporate strategy officer and chief of staff at Takeda,
and has held multiple leadership roles with the company around the
world. Mr. Furuta holds an MBA from The Wharton School of the
University of Pennsylvania and a bachelor’s degree in international
affairs from Hitotsubashi University in Japan.
“It gives me great confidence to know that Milano, a long-time
Takeda colleague, is stepping into this role,” said Mr. Weber.
“Milano’s global experience and exceptional leadership qualities
make him well-equipped to lead our talented finance organization. I
look forward to working with Milano more closely to deliver on our
commitment to investing in growth and shareholder returns.”
“It has been an honor to serve at Takeda and witness the
positive impact we’ve made in the lives of patients. I am immensely
proud of our successful transformation into a truly global
biopharmaceutical company with a well-managed debt profile, robust
cash flow and a long runway of profitable growth ahead. After 20
years working outside of Australia, I’m now looking forward to
returning home to be closer to family. I’ve had the pleasure of
working closely with Milano as a member of the Takeda Executive
Team and I’m fully confident that his experience, financial
background and strong leadership capabilities will help to ensure
that Takeda remains focused on delivering on its commitments to
shareholders,” said Costa Saroukos.
“I am honored and excited to take on the role of CFO of Takeda.
I wish Costa all the best on his return to Australia and I look
forward to building on his legacy and contributing to Takeda as a
global, values-based, R&D-driven biopharmaceutical leader,”
said Milano Furuta.
About Takeda Takeda is focused on creating better health
for people and a brighter future for the world. We aim to discover
and deliver life-transforming treatments in our core therapeutic
and business areas, including gastrointestinal and inflammation,
rare diseases, plasma-derived therapies, oncology, neuroscience and
vaccines. Together with our partners, we aim to improve the patient
experience and advance a new frontier of treatment options through
our dynamic and diverse pipeline. As a leading values-based,
R&D-driven biopharmaceutical company headquartered in Japan, we
are guided by our commitment to patients, our people and the
planet. Our employees in approximately 80 countries and regions are
driven by our purpose and are grounded in the values that have
defined us for more than two centuries. For more information, visit
www.takeda.com.
Important Notice For the purposes of this notice, “press
release” means this document, any oral presentation, any question
and answer session and any written or oral material discussed or
distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this press release. This press release (including any
oral briefing and any question-and-answer in connection with it) is
not intended to, and does not constitute, represent or form part of
any offer, invitation or solicitation of any offer to purchase,
otherwise acquire, subscribe for, exchange, sell or otherwise
dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are
being offered to the public by means of this press release. No
offering of securities shall be made in the United States except
pursuant to registration under the U.S. Securities Act of 1933, as
amended, or an exemption therefrom. This press release is being
given (together with any further information which may be provided
to the recipient) on the condition that it is for use by the
recipient for information purposes only (and not for the evaluation
of any investment, acquisition, disposal or any other transaction).
Any failure to comply with these restrictions may constitute a
violation of applicable securities laws. The companies in which
Takeda directly and indirectly owns investments are separate
entities. In this press release, “Takeda” is sometimes used for
convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our”
are also used to refer to subsidiaries in general or to those who
work for them. These expressions are also used where no useful
purpose is served by identifying the particular company or
companies. The product names appearing in this document are
trademarks or registered trademarks owned by Takeda, or their
respective owners.
Forward-Looking Statements This press release and any
materials distributed in connection with this press release may
contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of
operations, including estimates, forecasts, targets and plans for
Takeda. Without limitation, forward-looking statements often
include words such as “targets”, “plans”, “believes”, “hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”,
“may”, “should”, “would”, “could”, “anticipates”, “estimates”,
“projects” or similar expressions or the negative thereof. These
forward-looking statements are based on assumptions about many
important factors, including the following, which could cause
actual results to differ materially from those expressed or implied
by the forward-looking statements: the economic circumstances
surrounding Takeda’s global business, including general economic
conditions in Japan and the United States; competitive pressures
and developments; changes to applicable laws and regulations,
including global health care reforms; challenges inherent in new
product development, including uncertainty of clinical success and
decisions of regulatory authorities and the timing thereof;
uncertainty of commercial success for new and existing products;
manufacturing difficulties or delays; fluctuations in interest and
currency exchange rates; claims or concerns regarding the safety or
efficacy of marketed products or product candidates; the impact of
health crises, like the novel coronavirus pandemic, on Takeda and
its customers and suppliers, including foreign governments in
countries in which Takeda operates, or on other facets of its
business; the timing and impact of post-merger integration efforts
with acquired companies; the ability to divest assets that are not
core to Takeda’s operations and the timing of any such
divestment(s); the extent to which our internal energy conservation
measures and future advancements in renewable energy or low carbon
energy technology will enable us to reduce our greenhouse gas
emissions; and other factors identified in Takeda’s most recent
Annual Report on Form 20-F and Takeda’s other reports filed with
the U.S. Securities and Exchange Commission, available on Takeda’s
website at:
https://www.takeda.com/investors/sec-filings-and-security-reports/
or at www.sec.gov. Takeda does not undertake to update any of the
forward-looking statements contained in this report or any other
forward-looking statements it may make, except as required by law
or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this
report may not be indicative of, and are not an estimate, forecast,
guarantee or projection of Takeda’s future results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240131495750/en/
Global Media Brendan Jennings
brendan.jennings@takeda.com
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
Von Mai 2023 bis Mai 2024